TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS?

Authors :: John Cleland
Marco Metra
Daniel Bloomfield
Douwe Postmus
Mattia A.E. Valente
Adriaan A. Voors
Michael Givertz
Beth Davison
Gad Cotter
Piotr Ponikowski
Dirk J. van Veldhuisen
John Teerlink
Peter van der Meer
Hans L. Hillege
Licette C. Y. Liu
Christopher M. O'Connor
Source :: Journal of the American College of Cardiology. 65(10)
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.
Abstract: Over the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been neutral or shown harm. Biomarker profiles might identify subsets of patients that respond. We studied the effect of rolofylline on 180 day mortality across 24 clinical

Subjects :: medicine.medical_specialty
business.industry
medicine.disease
Rolofylline
Clinical trial
Non responders
chemistry.chemical_compound
chemistry
Heart failure
medicine
Biomarker (medicine)
Intensive care medicine
business
Cardiology and Cardiovascular Medicine

Full Text Access

Tools